Literature DB >> 18443267

A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn.

Mette Kjaer Killie1, Anne Husebekk, Jens Kjeldsen-Kragh, Bjørn Skogen.   

Abstract

BACKGROUND: Neonatal alloimmune thrombocytopenia is most commonly due to transplacental passage of maternal anti-HPA 1a antibodies. A prospective study was carried out to evaluate the pattern and quantity of maternal anti-HPA 1a antibodies in order to predict the level of thrombocytopenia in the neonates. DESIGN AND METHODS: A monoclonal antibody immobilization of platelet antigen assay was used to detect antibodies in maternal samples from 1,990 HPA 1bb women. HLA DRB3*0101 typing was performed in all immunized women by sequencing the HLA DRB3 gene when present.
RESULTS: Primary immunization more often took place in connection with delivery than during the first pregnancy. There was a strong correlation between maternal antibody levels and the platelet counts in the newborn (R(2) = 0.49, p < 0.001). A maternal antibody level above 3.0 IU/mL measured in gestational week 22 or 34 had a diagnostic sensitivity and specificity of 93% and 63%, respectively, for predicting the grade of neonatal thrombocytopenia. The women who were negative for HLA DRB3*0101 had significantly lower anti-HPA 1a antibody levels than those who were HLA DRB3*0101 positive (p < 0.007). In contrast to primigravida, in whom anti-HPA 1a antibody levels increased during pregnancy, the antibody level decreased in 92 of 147 women who had been pregnant previously (P(92 or more of 147) = 0.003). The anti-HPA 1a antibody level regularly increased after delivery.
CONCLUSIONS: Maternal anti-HPA 1a antibody levels in weeks 22 and 34 of pregnancy are good predictors of the degree of thrombocytopenia in the newborn both in the first and subsequent pregnancies. Most mothers became immunized at the time of delivery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443267     DOI: 10.3324/haematol.12515

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  21 in total

1.  Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion.

Authors:  Günther Giers; Folker Wenzel; Markus Stockschläder; Regina Riethmacher; Horst Lorenz; Boris Tutschek
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

2.  Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome.

Authors:  Jens Kjeldsen-Kragh; Dean A Fergusson; Mette Kjaer; Lani Lieberman; Andreas Greinacher; Michael F Murphy; James Bussel; Tamam Bakchoul; Stacy Corke; Gérald Bertrand; Dick Oepkes; Jillian M Baker; Heather Hume; Edwin Massey; Cecile Kaplan; Donald M Arnold; Shoma Baidya; Greg Ryan; Helen F Savoia; Denise Landry; Nadine Shehata
Journal:  Blood Adv       Date:  2020-07-28

3.  In HPA 1a-immunized women the decrease in anti-HPA 1a antibody level during pregnancy is not associated with anti-idiotypic antibodies.

Authors:  Jens Kjeldsen-Kragh; Michael Kim; Mette Kjaer Killie; Anne Husebekk; John Freedman; John W Semple
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

4.  Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers.

Authors:  Cedric Ghevaert; Nina Herbert; Louise Hawkins; Nicola Grehan; Philip Cookson; Steve F Garner; Abigail Crisp-Hihn; Paul Lloyd-Evans; Amanda Evans; Kottekkattu Balan; Willem H Ouwehand; Kathryn L Armour; Mike R Clark; Lorna M Williamson
Journal:  Blood       Date:  2013-05-08       Impact factor: 22.113

5.  HLA-DRB3*01:01 exhibits a dose-dependent impact on HPA-1a antibody levels in HPA-1a-immunized women.

Authors:  Jens Kjeldsen-Kragh; Thomas L Titze; Benedicte Alexandra Lie; John T Vaage; Mette Kjær
Journal:  Blood Adv       Date:  2019-04-09

Review 6.  Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management.

Authors:  Julie A Peterson; Janice G McFarland; Brian R Curtis; Richard H Aster
Journal:  Br J Haematol       Date:  2013-02-06       Impact factor: 6.998

7.  Fetal and neonatal alloimmune thrombocytopenia.

Authors:  Simona Constantinescu; Vlad Zamfirescu; Prof Radu Vladareanu
Journal:  Maedica (Buchar)       Date:  2012-12

8.  Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin.

Authors:  N Margreth Van Der Lugt; Marije M Kamphuis; Noortje P M Paridaans; Anouk Figee; Dick Oepkes; Frans J Walther; Enrico Lopriore
Journal:  Blood Transfus       Date:  2014-06-19       Impact factor: 3.443

9.  Fetal and neonatal alloimmune thrombocytopenia.

Authors:  J P Espinoza; J Caradeux; Errol R Norwitz; S E Illanes
Journal:  Rev Obstet Gynecol       Date:  2013

Review 10.  Disorders of the fetomaternal unit: hematologic manifestations in the fetus and neonate.

Authors:  L Vandy Black; Akhil Maheshwari
Journal:  Semin Perinatol       Date:  2009-02       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.